Skip to content

Our History

The story of Coala Life started in Lund in the spring of 2001. Over dinner, some medical students and IT experts discussed the problems associated with cardiac auscultation. Their frustration was evident. Heart problems are one of the main causes of death globally, at the same time, doctors around the world are still listening to hearts with equipment invented in the mid-1800s and that has not been updated since the 1930s – the stethoscope. The low-frequency sounds of the heart are difficult to hear, even with a stethoscope, other sounds, such as breathing, also disrupt the diagnostic process. The resulting diagnosis therefore often represents a subjective assessment by the listening doctor, where the practitioner’s experience becomes a critical factor. There must be a better way.

This is when the idea of creating the stethoscope of tomorrow was born: a solution that replaces subjectivity with objectivity and enhances and filters sound to improve cardiac auscultation. Originally intended for doctors, it gradually became clear that the individual patient is an equally, if not more, important product user.

The digital journey had begun
A range of experts within and outside healthcare services became involved. The development of the product and solution goes on for several years. The technological development of services involving smartphones, apps, cloud services, and wireless solutions become commonplace and benefits what will eventually become the end product.

In 2015, a group of entrepreneurs co-founded and created Coala Life. In a very short time, the Coala Heart Monitor is launched with the possibility of connecting every individual with a doctor through cloud services. Heart and lung screening carried out by the patient in their own home and technology to enhance and filter the sound is the way forward. Patent applications are filed and approved. The technology makes it possible to seriously take on the fight against one of the world’s leading causes of human death – heart disease.

The digital journey had begun
Focusing on chronic illnes care in the US
Focusing on chronic illnes care in the US
In 2022, Coala Life increased its focus on the US market through the acquisition of Vitrics Management Group, Inc., a service company offering managed Remote Patient Monitoring (mRPM). Remote Patient Monitoring (RPM) is a healthcare model that developed rapidly accelerated by the Covid-19 pandemic. RPM is now reimbursed by all US insurance companies and millions of patients are regularly followed remotely by their healthcare providers. To qualify as an RPM patient, a person must have an acute or chronic medical condition, which over 150 million Americans have.

Through the acquisition of Vitrics and the establishment of our own Managed RPM monitoring center, under the name QorumPartners, Coala Life expands its business in the US. Through QorumPartners, we manage patient monitoring, maintain ongoing patient contact, and ensure correct and regular monitoring. We follow patients 24/7 and report any abnormalities directly to the healthcare provider. We also handle administration and invoicing to the insurance system, which allows clinics to focus on their core business.

A vision to win the battle against heart disease
We operate in an evolved ecosystem that has been approved in Europe, the US, and elsewhere. Over SEK 400 million has been invested in the company, now publicly traded, and the unique Coala system, which is protected by around 30 patents and represents a close fit with digitalised healthcare services.

The ability to expand opportunities derived from heart diagnostics into other fields where remote diagnostics can be used is what drives our progress toward achieving our vision: Winning the fight against the number one cause of death globally – heart disease.

  • New study published validating diagnostic precision of Coala Heart Monitor.
  • Coala raises approximately SEK 84 million in a fully guaranteed rights issue.
  • Coala raises SEK 150 million in a fully guaranteed rights issue
  • Health economic analysis by Swedish Dental and Pharmaceutical Benefits Agency shows cost-effectiveness of using Coala in primary care
  • Coala discloses a US business update including 10 new RPM agreements signed until end of first quarter
  • Coala Life receives FDA 510k clearance for remote lung auscultation and enhanced ECG algorithm
  • Completes acquisition of Texas-based Vitrics Health, a solution provider for Remote Patient Monitoring
  • Coala Life enters into a convertible loan facility of SEK 25 M with existing shareholders.
  • RedHeart Study published proving that the Coala helps reduce symptoms of palpitations and increases quality of life in over 800 women
  • Coala introduced for post-Ablation monitoring at one of the leading US healthcare system
  • Launch of service to help enhance and leverage cardiac rehab programs.
  • Protocol for using Coala on long-term management of patients with palpitation issues and related symptoms.
  • Launch of new unique features including Coala Automated Monitoring Report and enhanced sound filters for remote auscultation.
  • Launch of managed RPM by Coala to help providers run seamless and compliant RPM programs.
  • TGA approval in Australia
  • Coala announces reverse IPO into Nasdaq Stockholm via acquisition by RNB
  • Partnership with Region Gävleborg and researchers of Karolinska Institute to run a 3 month study on patients with diabetes using the Coala platform
  • Coala awarded the 2021 Frost & Sullivan New Product Innovation Award – Cardiac Monitoring.
  • The TITAN-DM study where Coala is used long-term on people with diabetes is fully recruited with 600 participants
  • Coala goes public on Nasdaq First North Stockholm (Nasdaq: COALA.ST)
  • Launch of home enrollment service in the US to help reduce risk of COVID-exposure
  • Scientific data presented at the AHA EPI 2020 meeting in Phoenix confirmed again the superior accuracy of the Coala Heart Monitor
  • Coala Life pioneers new post-procedure protocol in partnership with Dr Reginald Abraham, a leading US cardiothoracic surgeon based in CA, USA
  • Coala is awarded with the Cardiology 2.0 Impact Award for 2020
  • Expanded FDA indication to allow for automatic detection of 9 of the most common arrhythmias during COVID-19 emergency
  • Expanded FDA indication to allow for lung sound monitoring during COVID-19 emergency
  • Perry Virtual first major rural health program in US to use Coala for remote monitoring
  • TEASE-study is published in BMJ validating the use of Coala for post-cryptogenic stroke monitoring
  • Coala Life and MyCardiologist to roll-out the largest Real-Time Cardiac Monitoring program in Florida
  • Coala Life rolls out in major cardiology clinics in Texas and California
  • Launch of the Coala Connect Rx direct-to-patient telecardiology service in the US
  • Coala introduced as screening tool of athletic students returning back from Covid-19 at one of US largest high schools
  • First patient-reported feasibility study of Coala published in BMJ, with excellent patient feedback
  • Coala Life signs commercialisation agreement with Apotek Hjärtat, the largest Pharmacy retailer in Sweden
  • Coala Heart Monitor is cleared by the FDA.
  • Coala Life is recognized as one of 100 top Global leaders in Digital Health by The Journal of mHealth
  • Coala Life Inc is established on the US market and first team on board. Coala enters the German market in partnership with Arteriomed GmbH.
  • Microsofts CEO Satya Nadella highlights Coala Life as major game changer in healthcare part of his keynote presentation in Stockholm
  • Coala Life elected by as the leading MedTech startup in Sweden.
  • Coala Life elected by Norrsken as one of the #theimpact100 companies, with goal and passion to solve global challenges.
  • Coala Life secures A-series funding of total USD 11 million for expansion into the US market.
  • New research presented confirming the leading clinical accuracy of the Coala Heart Monitor.
  • Coala Life is listed by the Wired as one of the 100 hottest start-ups in Europe.
  • Clinical performance results are presented on the Digital Health stage at the world’s largest cardiology meeting – European Society of Cardiology (ESC) – including results from the Red Heart Study.
  • Coala Life expands into the US market with office in Irvine, CA, and sales team spread across USA.
  • Coala partners with Luscii and enters the Dutch market
  • Coala Life enters technology partnership with multi-billion medical device company Asahi Kasei in Japan to expand into Heart Failure market
  • Coala Life partners with California-based High Desert Heart Institute as the first major healthcare provider contract for Coala Life in the US
  • Aleris, one of the largest healthcare providers in Northern Europe, completes a successful evaluation and clinical implementation of the Coala Heart Monitor at the Sabbatsberg Hospital.
  • First patients diagnosed and treated for Atrial Fibrillation in the US thanks to Coala
  • Coala’s US advisory board assembled with leading industry professionals
  • The University Hospital in Lund starts using the Coala Pro for smart and Digital cardiac assessments.
  • Coala Life wins the Startup World Cup finals in Sweden and heading for the global grand finale in Silicon Valley.
  • Coala life winner of The Digital Hospital Award 2018, voted by the most prominent hospital managers in Switzerland and Austria.
  • Coala Life is recognized by Red Herring as one of Europe’s Top-100 start-ups.
  • Coala Life wins the People’s Choice Award of the prestigious 2018 Grand Award of Design.
  • Publishing of clinical performance data at the 2018 Spring Cardiovascular Spring meeting in Stockholm.
  • Results from joint-project with Praktikertjänst (the largest private healthcare provider in Sweden) is presented proving a reduction in specialist referrals with almost 40%, with reduced costs and satisfied users as results.
  • Coala Life winner of Makerstown Jury’s Award 2018 in Brussels competing with 40 other leading European innovation companies
  • Coala Life celebrates 100,000 ECG-measurements carried out in Sweden
  • Coala Life becomes partner to The RedHeart Study, managed by Karolinska Institutet. At the time the most comprehensive study investigating the female heart through digital monitoring.
  • Coala Life raises SEK 16 million with major investors to accelerate commercialisation of the product.
  • Coala Life starts its collaboration with Capio and Euro Accident.
  • Coala presents at the Health 2.0 conference in Santa Clara, US.
  • Coala attends and presents at the Digital Health Pavilion of ESC 2018, the largest cardiovascular meeting in the world with more than 30,000 participants.
  • Coala named “Cool Vendor 2018” by Gartner.
  • Coala Life signs agreement with a company from the Aleris group to evaluate new solutions and methods to digitalise cardiac healthcare.
  • PUBLIC Research and Investment Institute Coala Life names names Coala Life as one of the companies leading digital transformation.
  • Coala introduces new, unique algorithms with advanced P-wave detection and compatibility with Apple Health Records.
  • Performance assessment study presented at American Heart Association 2018, and published in Circulation.
  • The Coala is launched in Sweden and sold online and in retail by LloydsPharmacy in Sweden.
  • Coala Life is a proud winner and part of “Sweden’s 33 hottest tech companies list 2017”.
  • Coala Life as category finalist in Connected Health during the Swedish Mobile Awards.
  • Launch of the Coala Pro, a unique digital solution for caregivers and professional users to enable efficient, high performance yet simple arrhythmia assessments as well as diagnosing and managing patients with AFIB.
  • Coala Life wins the prestigious eHealthAward 2017, handed over by the Swedish Minister of Health.
  • Coala Life is awarded the prestigious Rising Star Award 2017 at the Swedish American Life Science Summit.
  • Coala is used in unique new clinical study on stroke patients.
  • Coala Life signs deal with global life science company Bayer. Read article here.
  • Coala Life raises additional growth capital and extends the Board.
  • Coala receives a major grant from the Swedish Governmental agency for Innovation Systems (Vinnova) to further develop Artificial Intelligence to enable early prediction of heart disease.

Coala is CE-approved and Coala Life is ISO 13485 certified.

Coala Life AB is founded after the fourth generation technology platform and analysis algorithms are successfully verified.

Coala research is initiated by Swedish entrepreneurs and physicians with the goal of developing wireless systems for digital monitoring and diagnosing of the heart.